Research progress on intranasal treatment for Parkinson's disease
Abstract Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder globally, significantly affecting the quality of life of affected individuals. Systemic drug delivery to the brain is inefficient because of first‐pass metabolism, the blood‐brain barrier (BBB), and the bl...
Saved in:
| Main Authors: | Puyuan Wen, Chao Ren |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-06-01
|
| Series: | Neuroprotection |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/nep3.42 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intranasal Administration as a Route to Deliver Drugs to the Brain (Review)
by: N. N. Porfiryeva, et al.
Published: (2021-11-01) -
Development and study of mucoadhesive microcapsules for the nasal levodopa delivery
by: D. S. Gordeeva, et al.
Published: (2024-11-01) -
Therapeutic Efficacy of Small Extracellular Vesicles Loaded with ROCK Inhibitor in Parkinson’s Disease
by: Candy Carbajal, et al.
Published: (2025-03-01) -
The Nasal–Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases
by: Yi Qiu, et al.
Published: (2025-06-01) -
Intranasal Transplantation of Microbiota Derived from Parkinson’s Disease Mice Induced Astrocyte Activation and Neurodegenerative Pathology from Nose to Brain
by: Yi-Meng Xia, et al.
Published: (2025-04-01)